drugset / Trial / NCT01823991
COGNUTRIN in Breast Cancer Survivors
Phase 0
Completed
36 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Gateway for Cancer Research · collabUniversity of South Florida · collab
RandomizedParallel-groupTriple-blindSupportive care
Summary
The purpose of this study is to examine the safety and influence of an intervention (COGNUTRIN) using nutritional supplements (n-3 fatty acids and blueberry anthocyanins) on cognitive performance in breast cancer survivors following chemotherapy. The investigators' goal is to treat or lessen the late effects of cancer treatment. The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza.
Timeline
- Start
- 2014-07-30
- Primary completion
- 2017-04-05
- Completion
- 2018-05-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lovaza | Other / unclassified | — | — |
| Subject | VitaBlue | Unknown | — | — |